Changeflow GovPing Healthcare & Life Sciences Pyrimido pyrimidinone compound and pharmaceutic...
Routine Rule Added Final

Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted Patent US12590098B2 to Axceso Biopharma Co., Ltd. on March 31, 2026, covering a pyrimido pyrimidinone compound that inhibits PD-L1 expression for cancer treatment. The patent includes 9 claims and names 8 inventors including Young Jun Park and Sung Jun Park.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted Patent US12590098B2 to Axceso Biopharma Co., Ltd. for a pyrimido pyrimidinone compound effective as a PD-L1 inhibitor for cancer treatment or prevention. The patent (Application No. 18245395, filed September 15, 2021) contains 9 claims and is classified under CPC C07D 487/04.

No immediate compliance action is required by regulated entities. This is a routine patent grant that establishes intellectual property rights for the assignee. Third parties seeking to use or develop similar compounds should conduct freedom-to-operate analyses and respect the patent's claim scope.

Archived snapshot

Mar 31, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same

Grant US12590098B2 Kind: B2 Mar 31, 2026

Assignee

AXCESO BIOPHARMA CO., LTD.

Inventors

Young Jun Park, Sung Jun Park, Hyebin Yoo, Hyunnam Song, Si-Eun Yun, Sojin Park, Joon Woo Kim, Sung Il Yoon

Abstract

Diclosed are a pyrimido pyrimidinone compound having an effect of inhibiting PD-L1 expression, a pharmaceutical composition containing the pyrimido pyrimidinone compound as an active ingredient, and uses of the compound or composition. The pyrimido pyrimidinone compound can be effectively used for the treatment or prevention of cancer.

CPC Classifications

C07D 487/04

Filing Date

2021-09-15

Application No.

18245395

Claims

9

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12590098B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Pharmaceutical Compound Development Drug Manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Intellectual Property
Topics
Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!